Clinical trial · Observational
Immune Checkpoint Receptors in AML-Leukemic Initiating Cells
Analysis of Immune Checkpoint Receptors Expression in the LIC Fraction pf AML Cells - ICAML-LIC
NCT03449745CI-TRIAL-00057940ICAML-LICcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This project aim at deciphering immune mechanisms that allow the immunoescape of AML initiating cells.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Immune checkpoints (ICP) ligand expression
- timeFrame
- At inclusion
- description
- Compare large panel of ICP ligand expression between LIC and HSC by flow cytometry
Secondary outcomes (2)
- measure
- Levels of ICP ligand expression
- timeFrame
- At inclusion
- description
- Compare levels of ICP ligand expression according to FAB classification, cytogenetic classification and molecular abnormalities
- measure
- Levels of ICP ligand expression
- timeFrame
- At inclusion
- description
- Study levels of ICP ligand expression on minimal residual disease
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * ≥ 18 years of age * newly diagnosed AML Exclusion Criteria: * isolated extramedullary AML * mixed phenotype acute leukemia
References
Publications (0)
Data not yet available
No reference posted for this study.